Abbott will develop assay for Janssen-Pharmacyclics leukemia drug

02/22/2013 | GenomeWeb Daily News (free registration) · Yahoo

Abbott Laboratories agreed to develop a fluorescence in situ hybridization-based companion diagnostic to determine which patients will benefit from ibrutinib, an experimental chronic lymphocytic leukemia drug being developed by Pharmacyclics and Johnson & Johnson's Janssen Biotech. The test will identify high-risk CLL patients with a deletion in chromosome 17p.

View Full Article in:

GenomeWeb Daily News (free registration) · Yahoo

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Program Coordinator/Lecturer for the Regulatory Science program
Johns Hopkins University
Washington, DC
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA